{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:28:16Z","timestamp":1759483696123},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephrol. Dial. Transplant."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1093\/ndt\/gfv305","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T02:59:36Z","timestamp":1440644376000},"page":"2068-2075","source":"Crossref","is-referenced-by-count":11,"title":["Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients"],"prefix":"10.1093","volume":"30","author":[{"given":"Medha","family":"Airy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreedhar","family":"Mandayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya A.","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara I.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Y.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,8,26]]},"reference":[{"key":"2016030623280608000_30.12.2068.1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","article-title":"FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease","volume":"85","author":"Lu","year":"2010","journal-title":"Am J Hematol"},{"key":"2016030623280608000_30.12.2068.2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101156"},{"key":"2016030623280608000_30.12.2068.3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02840608"},{"key":"2016030623280608000_30.12.2068.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.001"},{"key":"2016030623280608000_30.12.2068.5","doi-asserted-by":"publisher","DOI":"10.5414\/CN107397"},{"key":"2016030623280608000_30.12.2068.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.09.028"},{"key":"2016030623280608000_30.12.2068.7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015010052"},{"key":"2016030623280608000_30.12.2068.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.02.339"},{"key":"2016030623280608000_30.12.2068.9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012121164"},{"key":"2016030623280608000_30.12.2068.10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2016030623280608000_30.12.2068.11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10141013"},{"key":"2016030623280608000_30.12.2068.12","doi-asserted-by":"publisher","DOI":"10.5414\/CNP66348"},{"key":"2016030623280608000_30.12.2068.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05320513"},{"key":"2016030623280608000_30.12.2068.14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.6.1239"},{"key":"2016030623280608000_30.12.2068.15","doi-asserted-by":"publisher","DOI":"10.1159\/000083766"},{"key":"2016030623280608000_30.12.2068.16","doi-asserted-by":"publisher","DOI":"10.1080\/08860220802134631"},{"key":"2016030623280608000_30.12.2068.17","unstructured":"United States Food and Drug Administration. Potential Signals of Serious Risks\/New Safety Information Identified from the Adverse Event Reporting System (AERS) between April\u2013June 2010. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm223734.htm (28 February 2011, date last accessed)"},{"key":"2016030623280608000_30.12.2068.18","unstructured":"United States Food and Drug Administration. Letter from Robert Kane, MD, Deputy Division Director for Safety, Center for Drug Evaluation and Research to AMAG Pharmaceuticals Inc. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/022180s003,022180s005ltr.pdf (28 February 2011, date last accessed)"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/30\/12\/2068\/17172551\/gfv305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T19:25:25Z","timestamp":1718047525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfv305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,26]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,11,23]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1093\/ndt\/gfv305"],"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfv305","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,26]]}}}